A signature for immune response correlates with HCV treatment outcome in Caucasian subjects
-
Published:2015-06
Issue:
Volume:3
Page:56-61
-
ISSN:2352-3409
-
Container-title:Data in Brief
-
language:en
-
Short-container-title:Data in Brief
Author:
Hare Brian J.ORCID,
Haseltine Eric,
Fleming Mark,
Chelsky Daniel,
McIntosh Laura,
Allard Rene,
Botfield Martyn
Subject
Multidisciplinary
Reference12 articles.
1. B.J. Hare, E. Haseltine, M. Fleming, D. Chelsky, L. McIntosh, R. Allard, M. Botfield. A signature for immune response correlates with HCV treatment outcome in Caucasian subjects, 116 (2015) 59–67, http://dx.doi.org/10.1016/j.jprot.2014.12.015.
2. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study;Gane;J. Hepatol.,2013
3. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/− Ribavirin in patients with chronic HCV GT1 infection: results from the aviator study;Kowdley;J. Hepatol.,2013
4. INCIVEK [US Prescribing Information]. No Title. 〈http://pi.vrtx.com/files/uspi_telaprevir.pdf〉, 2013.
5. 60 SILEN-C1: Sustained Virologic Response (SVR) and safety of BI201335 combined with peginterferon alfa-2A and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection;Sulkowski;J. Hepatol.,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献